In a bid to achieve ambitious sales target of $1 billion by FY2018, Biocon has hired the services of global consulting giant McKinsey to create a new structure. McKinsey is advising Biocon on an effective and scalable organisation structure to deliver on our ambitious and differentiated growth strategy
At present, the company is focusing on five key business verticals - small molecules comprising complex APIs (active pharmaceutical ingredients), biosimilars including affordable insulins and MAbs (monoclonal antibodies), novel molecules including biologicals for diabetes and autoimmune diseases, and value added generics and branded formulations - in addition to integrated research services through its subsidiary Syngene.
On the consolidated basis, the company reported 8.14% rise in its net profit at Rs 91.76 crore for the third quarter ended December 31, 2012 as compared to Rs 84.85 crore for the same quarter in the previous year. Total income of the company increased by 23.14% at Rs 659.65 crore for quarter under review as compared to Rs 535.69 crore for the quarter ended December 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: